



Press release

DiagnOptics and PATH partner on clinical research project on diabetes screening in India.

Groningen, the Netherlands – February 6, 2012

DiagnOptics and PATH partner on a clinical study in which the performance of point-of-care technologies for diabetes screenings will be tested in India. DiagnOptics' recently launched Diab-spot will be tested and further developed in this clinical study in India.

There is a strong need to evaluate point-of-care (POC) technologies for diabetes screening in Indian settings and compare their performance with existing technologies. Through this study, the investigators will explore whether a testing model can guide disease treatment and management without the routine use of laboratory measurements. This study focuses on technologies that measure advanced glycation endproducts (AGEs) (such as the AGE Reader and Diab-spot) and glycemic control by POC glycated hemoglobin (HbA1c) readers.

Diab-spot offers a noninvasive and convenient method for diabetes screening with an immediate screening result on the spot. "DiagnOptics is convinced that Diab-spot can make a difference in the mission to find undiagnosed diabetics," says DiagnOptics managing director, Bart van den Berg.

The principal investigator of this research project is Dr. Bernhard H. Weigl from the United States collaborator, PATH. The study is funded under PATH's Center for POC Diagnostics for Global Health, which is supported by National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering (NIBIB). The Indian principal investigator is Dr. V. Mohan from the Madras Diabetes Research Foundation (MDRF) Chennai, India. PATH and MDRF hope that results from this study will provide the basis for larger programmatic activities to use and benefit from the novel low-cost technical approaches in the areas of diabetes screening and control in India.

About DiagnOptics

DiagnOptics is the pioneer and inventor of cutting-edge diagnostic devices that can noninvasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of AGEs has led to the invention of the AGE Reader—a state-of-the-art diagnostic device that can determine the tissue accumulation of AGEs in 30 seconds. Since obtaining the CE certification on the AGE Reader in 2006, DiagnOptics has been marketing this medical device to hundreds of clinics around the world. Currently the company is working on obtaining additional regulatory approvals in other regions and is engaged in new product development activities. The head office of DiagnOptics Technologies BV is in Groningen, the Netherlands.

[Read more](#)

About AGE Reader Technology

The AGE reader technology is the answer to the need for measuring AGEs without the disadvantages of the existing methods. The AGE Reader technology is used in both the AGE Reader and Diab-spot. This state-of-the-art device provides a simple noninvasive solution that allows clinicians to determine the AGE level within 30 seconds.

[Read more](#)



About Diab-spot

DiagnOptics was the first company worldwide to introduce a technology to noninvasively measure the tissue accumulation of AGEs by means of fluorescence techniques (the AGE reader). Diab-spot features this AGE measurement and combines it with a small number of patient characteristics to calculate the Diab-spot test result. These simple characteristics include questions about other well-known diabetes risk factors, which can be easily answered on the touch screen. Diab-spot yields an immediate screening result on the spot.

[Read more](#)

About PATH

PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps to provide appropriate health technologies and vital strategies that change the way people think and act. PATH's work improves global health and well-being. For more information, please visit <http://www.path.org>.

About MDRF (Madras Diabetes Research Foundation)

Madras Diabetes Research Foundation (MDRF) was established in 1996 by Dr. V. Mohan, internationally acclaimed diabetologist and research scientist and his late wife Dr. Rema Mohan, internationally known specialist in diabetic eye disorders. MDRF was founded with the vision of providing a world class environment for research in diabetes and its complications. Within its short span of existence, MDRF has built up strengths in basic, clinical, and epidemiological research. The quality of its research in diabetes and its complications is evidenced by numerous original publications in reputed peer-reviewed journals. The institute also collaborates with several international and national centres.

Contact

Bart van den Berg
Managing Director
tel: +31 (0)6 54228480
email: b.vandenberg@diagnoptics.com

DiagnOptics Technologies B.V.
L.J. Zielstraweg 1, Meditech Center
9713 GX Groningen
the Netherlands
www.diagnoptics.com

Amy MacIver
Media Relations Officer
tel: 206.302.4522
email: amaciver@path.org

PATH
PO Box 900922
Seattle, WA 98109 USA
<http://www.path.org>